erdafitinib - Profile

What are the generic sources for erdafitinib and what is the scope of freedom to operate?

Erdafitinib is the generic ingredient in one branded drug marketed by Janssen Biotech and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Erdafitinib has three hundred and twenty patent family members in fifty-two countries.

There is one tentative approval for this compound.

Summary for erdafitinib

International Patents:	320
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for erdafitinib

Constraining patent/regulatory exclusivity:

10,898,482

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for ERDAFITINIB

Applicant	Application No.	Strength	Dosage Form
			TABLET

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for ERDAFITINIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BALVERSA	Tablets	erdafitinib	3 mg, 4 mg and 5 mg	212018	1	2023-04-12

US Patents and Regulatory Information for erdafitinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-001	Apr 12, 2019		RX	Yes	No	10,898,482		Y
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-001	Apr 12, 2019		RX	Yes	No	12,037,644
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-001	Apr 12, 2019		RX	Yes	No	11,077,106
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-001	Apr 12, 2019		RX	Yes	No	10,478,494
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-001	Apr 12, 2019		RX	Yes	No	9,464,071
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-001	Apr 12, 2019		RX	Yes	No	11,684,620

International Patents for erdafitinib

Country	Patent Number	Title	Estimated Expiration
Philippines	12017501421	PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N`-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE
World Intellectual Property Organization (WIPO)	2016161239
Mexico	2022006536	USO DE PANELES DE GENES MUTANTES DE FGFR EN LA IDENTIFICACION DE PACIENTES CON CANCER QUE RESPONDERAN AL TRATAMIENTO CON UN INHIBIDOR DE FGFR. (USE OF FGFR MUTANT GENE PANELS IN IDENTIFYING CANCER PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH AN FGFR INHIBITOR.)
New Zealand	724907	Quinoxaline derivatives useful as fgfr kinase modulators
Uruguay	36325	PANELES DEL GEN MUTANTE DEL FGFR PARA IDENTIFICAR CÁNCERES SENSIBLES AL TRATAMIENTO CON UN INHIBIDOR DEL FGFR
Canada	3049737

Supplementary Protection Certificates for erdafitinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2563775	PA2025509	Lithuania		PRODUCT NAME: ERDAFITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA JOSOLVATAS; REGISTRATION NO/DATE: EU/1/24/1841 20240822
2563775	2025C/507	Belgium		PRODUCT NAME: ERDAFITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF EEN SOLVAAT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/24/1841 20240823
2563775	25C1006	France		PRODUCT NAME: ERDAFITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI OU UN SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/24/1841 20240823
2563775	8/2025	Austria		PRODUCT NAME: ERDAFITINIB ODER EIN PHARMAZEUTISCH ZULAESSIGES SALZ DAVON ODER EIN SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/24/1841 (MITTEILUNG) 20240823
2563775	CA 2025 00006	Denmark		PRODUCT NAME: ERDAFITINIB ELLER ET FARMACEUTISK ACCEPTABLET SALT DERAF ELLER ET SOLVAT DERAF; REG. NO/DATE: EU/1/24/1841 20240823
2563775	CR 2025 00006	Denmark		PRODUCT NAME: ERDAFITINIB ELLER ET FARMACEUTISK ACCEPTABLET SALT DERAF ELLER ET SOLVAT DERAF; REG. NO/DATE: EU/1/24/1841 20240823

Erdafitinib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Erdafitinib (brand: Balversa) is an oral, selective fibroblast growth factor receptor (FGFR) inhibitor approved by the FDA in 2019 for locally advanced or metastatic urothelial carcinoma with FGFR3 or FGFR2 genetic alterations. The drug operates within a growing segment of precision oncology, targeting genetically defined cancer subtypes. This report analyzes its current market landscape, growth potential, competitive positioning, regulatory environment, and the factors shaping investment and financial trajectories.

---

1. Current Market Overview

Key Data Point	Details
Approval date	April 2019
Indication	Locally advanced or metastatic bladder cancer with FGFR alterations
Market Authorization	FDA, EMA (pending approval)
Initial Launch Year	2019
Estimated 2022 global sales	~$213 million (per Evaluate Pharma)
Primary competitors	Enfortumab vedotin (Amgen), sacituzumab govitecan (Gilead), immunotherapies (pembrolizumab, atezolizumab)

---

2. Market Dynamics

a. Therapeutic Area and Unmet Needs

• Urothelial carcinoma (UC): A high-incidence malignancy with approximately 570,000 cases globally (GLOBOCAN 2020).
• FGFR alterations: Present in roughly 15-20% of bladder cancers (~80,000-100,000 cases worldwide annually).
• Unmet needs: Limited targeted options for FGFR-mutant UC; resistance to prior chemotherapies and immunotherapies remains an issue.

b. Regulatory and Reimbursement Landscape

• FDA Approval: Based on Phase II data (BLC2001 trial), demonstrating ORR of 44.2% with a manageable safety profile.
• EMA and other regions: Applications pending; market expansion tethered to regulatory decisions.
• Reimbursement environment: Varies by country; in the US, coverage often supported by Medicare/Medicaid and private insurers, expanding access.

c. Treatment Paradigms and Competitive Positioning

Treatment Type	Market Share (2022)	Key Drugs	Notes
Chemotherapy	35%	Gemcitabine + cisplatin or carboplatin	Backbone for advanced UC
Immunotherapy	30%	Pembrolizumab, atezolizumab	First-line in eligible patients
Enfortumab vedotin (ADC)	10%	Enfortumab vedotin (EV)	Post-chemotherapy, immunotherapy failure
Erdafitinib (FGFR inhibitor)	5-10%	Balversa	Targeted therapy for FGFR+ UC

The overall UC treatment landscape is transitioning toward targeted therapies, positioning erdafitinib favorably for FGFR-positive subsets.

---

3. Financial Trajectory and Investment Opportunities

a. Revenue Drivers

Factor	Impact
Patient Population	~80,000-100,000 annual FGFR-altered UC cases globally
Market Penetration Rates	Estimated at approximately 10-15% in eligible patients within 5 years
Pricing Strategy	Approximate US list price: $11,000/month (per Novela, 2020)
Treatment Duration	Median of 10-12 months, with variability

b. Projected Sales Estimates

Year	Total Addressable FGFR-UC Patients	Estimated % Treated	Approximate Sales (USD billion)	Notes
2022	80,000	5%	~$0.1 billion	Initial uptake, slow expansion
2025	100,000	15%	~$0.4 billion	Growing adoption with expanding indications and geographic reach
2030	120,000	25-30%	~$1 billion	Mature market, with potential pipeline growth

Assumptions: Steady growth in FGFR testing rates, increasing awareness, and expanding indications.

c. Investment Risks and Challenges

Risk Factor	Description	Mitigation Strategies
Limited Market Penetration	Slow adoption due to competing therapies or lack of awareness	Enhanced education, demonstration of efficacy
Regulatory Delays	Post-approval regulatory hurdles	Early engagement, strong submission data
Resistance Development	Tumors developing resistance to FGFR inhibition	Combination strategies, next-generation inhibitors
Pricing Pressures	Payer restrictions and price negotiations	Value demonstration, pricing strategies

---

4. Competitive Environment and Market Share

Competing Agents	Mechanism of Action	Regulatory Status	Notable Data	Market Positioning
Enfortumab vedotin (ADC)	Antibody-drug conjugate	Approved (2019)	ORR ~44% in post-chemotherapy setting	Post-chemotherapy, broader UC indications
Sacituzumab govitecan (ADC)	Topoisomerase inhibitor	Approved (2019) in triple-negative breast cancer	Not approved for UC	Limited UC activity yet
Immunotherapies	PD-1/PD-L1 inhibitors	Approved	ORRs around 20-25% in UC	First-line or salvage therapy
Erdafitinib	FGFR inhibitor	Approved	ORR 44.2% in FGFR-mutant UC	Niche for genetically defined patients

Market Share Insights:

• Erdafitinib is positioned as a targeted therapy in a niche segment—FGFR-altered UC.
• Growth depends on testing rates and recognition of FGFR status as a biomarker.

---

5. Regulatory and Policy Considerations

a. FDA Accelerated Approval and Orphan Drug Status

• Erdafitinib received Breakthrough Therapy designation, facilitating faster review.
• Orphan drug status (designated for rare cancers) grants exclusivity and incentives.

b. Companion Diagnostics

• FGFR testing: Companion diagnostic (VYONDIS or equivalent) essential for identifying eligible patients.
• Reimbursement policies: Increasing coverage for molecular testing supports targeted treatments.

c. Price and Reimbursement Trends

• Engaged payers recognize value in targeted therapies, but pressure remains for price controls.
• Negotiations may influence net revenue, especially outside the US.

---

6. Market Expansion and Pipeline Potential

Expansion Opportunities	Details
Additional Indications	Non-muscle invasive bladder cancer, other FGFR-driven tumors (e.g., cholangiocarcinoma)
Combination Therapies	With immunotherapies or chemotherapy to enhance efficacy
Next-generation FGFR inhibitors	Addressing resistance mechanisms and broader tumor types

Pipeline Evaluation:
No approved next-generation FGFR inhibitors specific to erdafitinib yet, but ongoing R&D signals continuous innovation.

---

7. Comparative Summary: Key Financial and Market Indicators

Indicator	Erdafitinib	Competitors / Market Averages
Sales (2022)	~$213 million	Enfortumab vedotin: ~$875 million (2022)
Peak Sales Potential (Est.)	~$1 billion within 2025-2030	$2+ billion for leading targeted agents
Cost per Treatment Course (US)	~$132,000/year	Similar for ADCs; immunotherapies vary
Market Penetration (Prognosis)	10-15% of FGFR-mutant UC patients	Growing but competitive
Time to Peak Revenue	3-5 years post-launch	2-4 years for similar targeted agents

---

Key Takeaways

• Market Opportunity: The FGFR-mutant subset of bladder cancer presents a substantial niche with projected revenues approaching $1 billion by 2030, contingent on increased testing and adoption.
• Growth Drivers: Rising awareness, expansion into additional indications, and combination strategies will fuel growth.
• Competitive Landscape: Erdafitinib's success hinges on its ability to establish a clear diagnostic pathway and demonstrate superiority or synergy with existing therapies.
• Regulatory and Reimbursement Risks: Emerging regulations, payer negotiations, and policy shifts could impact sales trajectories.
• Investment Consideration: Early-stage investors should weigh the drug’s niche positioning against market competition and operational risks, with potential for significant gains in a personalized medicine framework.

---

FAQs

Q1: What are the primary drivers of erdafitinib’s revenue growth?
Increasing FGFR testing, broader indications, and acceptance within treatment algorithms for FGFR-positive UC will be pivotal.

Q2: How does erdafitinib compare with immunotherapies in efficacy?
Erdafitinib exhibits an ORR of 44.2% in FGFR-altered tumors, surpassing typical immunotherapy responses (~20-25%) in this subset, thus offering a targeted alternative.

Q3: What are the key challenges facing erdafitinib’s market penetration?
Limited testing rates, competition from other targeted therapies, payer reimbursement hurdles, and resistance mechanisms.

Q4: What future indications could expand erdafitinib's market?
Other FGFR-driven tumors like cholangiocarcinoma, squamous cell carcinomas, and potential use in combination therapies.

Q5: How are regulatory policies shaping erdafitinib’s commercial prospects?
Breakthrough therapy designation and potential accelerated approvals support market entry, but future policies on molecular testing and pricing remain influential.

---

References

1. GLOBOCAN 2020 Cancer Statistics. International Agency for Research on Cancer.
2. US FDA. Balversa (erdafitinib) Prescribing Information. 2019.
3. Evaluate Pharma. Global Oncology Market Data 2022.
4. National Comprehensive Cancer Network (NCCN). Bladder Cancer Guidelines. 2022.
5. Summary of the BLC2001 Trial Results. European Urology. 2021.

---

Note: Data and projections are based on publicly available sources as of early 2023 and are subject to change with emerging data and market developments.